Clinical role and mechanisms of action of analgesic nitrous oxide

References

• Alexander J. I., Hill R. G. Postoperative pain control. Blackwell, Oxford 1987; 124–125; 130
   Google Scholar
• Bergman J. Opioid modification of behavioural effects of cocaine in monkeys. Neuropsychopharmacology 1994; 10: 667S, (supplement 1)
   Google Scholar
• Carey C., Clark A., Saner A. Analgesic nitrous oxide for addictive withdrawal states in general practice. South African Medical Journal 1991; 79: 516
   PubMed Web of Science ®Google Scholar
• Daynes G. The initial management of alcoholism using oxygen and nitrous oxide: a transcultural study. International Journal of Neuroscience 1989; 49: 83–86
   PubMed Web of Science ®Google Scholar
• Di Chiara G., Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. Journal of Pharmacology and Experimental Therapeutics 1988; 244: 1067–1080
   PubMed Web of Science ®Google Scholar
• Dorris R. L., Truong V. Locomotor effects of nitrous oxide in mice: requirement of newly-synthesized and main intraneural storage pools of dopamine. Journal of Pharmacy and Pharmacology 1993; 45: 315–316
   PubMed Web of Science ®Google Scholar
• Ebert T. J. Differential effect of nitrous oxide on baroreflex control of heart rate and peripheral sympathetic nerve activity in humans. Anesthesiology 1990; 72: 16–22
   PubMed Web of Science ®Google Scholar
• Finck A. D. Nitrous oxide analgesia. Nitrous oxide/N₂O, E. I. Eger, II. Elsevier, New York 1985; 41–55
   Google Scholar
• Fujimoto J. M., Rady J. J. Intracerebroventricular physostigmine- induced analgesia: enhancement by naloxone, Beta-funaltrexamine and nor-binaltorphimine and antagonism by dynorphin A 1–17. Journal of Pharmacology and Experimental Therapeutics 1989; 251: 1045–1052
   PubMed Web of Science ®Google Scholar
• Gillman M. A. Minireview: Analgesic (sub anesthetic) nitrous oxide interacts with the endogenous opioid system: A review of the evidence. Life Science 1986; 39: 1209–1221
   PubMed Web of Science ®Google Scholar
• Gillman M. A. Haematological changes caused by nitrous oxide. Cause for concern? Editorial. British Journal of Anaesthesia 1987; 59: 143–146
   PubMed Web of Science ®Google Scholar
• Gillman M. A. Nitrous oxide abuse in perspective. Clinical Neuropharmacology 1992; 15: 297–306
   PubMed Web of Science ®Google Scholar
• Gillman M. A. Psychotropic analgesic nitrous oxide as an investigate, diagnostic and therapeutic tool. International Journal of Neuroscience 1994; 76: 1–3
   PubMedGoogle Scholar
• Gillman M. A., Lichtigfeld F. J. Possibility of an opioid and anti-opioid system. Journal of the Royal Society of Medicine 1981; 74: 943–944
   PubMed Web of Science ®Google Scholar
• Gillman M. A., Lichtigfeld F. J. The opioid and anti-opioid system in addiction. South African Medical Journal 1984; 66: 592
   PubMed Web of Science ®Google Scholar
• Gillman M. A., Lichtigfeld F. J. Minimal sedation required with nitrous oxide/oxygen of the alcohol withdrawal state. British Journal of Psychiatry 1986; 148: 604–606
   PubMed Web of Science ®Google Scholar
• Gillman M. A., Lichtigfeld F. J. Analgesic nitrous oxide: past present future. International Journal of Neuroscience 1989; 49: 75–81
   PubMed Web of Science ®Google Scholar
• Gillman M. A., Lichtigfeld F. J. Analgesic nitrous oxide for alcohol withdrawal: a critical appraisal after 10 years' use. Postgradraduate Medical Journal 1990; 66: 543–546
   PubMed Web of Science ®Google Scholar
• Gillman M. A., Lichtigfeld F. J. Placebo and analgesic nitrous oxide for the treatment of the alcohol withdrawal state. British Journal of Psychiatry 1991; 159: 672–675
   PubMed Web of Science ®Google Scholar
• Gillman M. A., Lichtigfeld F. J. Opioid properties of psychotropic analgesic nitrous oxide (laughing gas). Perspectives in Biology and Medicine 1994a; 38: 125–138
   PubMed Web of Science ®Google Scholar
• Gillman M. A., Lichtigfeld F. J. Pharmacology of psychotropic analgesic nitrous oxide as a multipotent opioid agonist. International Journal of Neuroscience 1994b; 76: 5–12
   PubMedGoogle Scholar
• Gillman M. A., Lichtigfeld F. J. NO Comments. Nature 1994c; 367: 28
   PubMedGoogle Scholar
• Gillman M. A., Matussek N., Lichtigfeld F. J. Effect of nitrous oxide on depressive patients and volunteers. Psychiatry: the state of the art, P. Berner. Plenum, New York 1985; 397–404
   Google Scholar
• Griffin G. C., Campbell V. D., Jones R. Nitrous oxide-oxygen sedation for minor surgery. Experience in a pediatric setting. Journal of the American Medical Association 1981; 245: 2411–2413
   Web of Science ®Google Scholar
• Hamilton W. K. Con: Nitrous oxide should be used for coronary heart disease. Journal of Cardiothoracic Surgery 1991; 44: 189–191
   Google Scholar
• Hughes J., Kosterlitz H. W. Opiate peptides. British Medical Bulletin 1977; 33: 157–161
   PubMed Web of Science ®Google Scholar
• Jaffe J. H., Martin W. R. Opioid analgesics and antagonists. Goodman and Oilman's the pharmacological basis of therapeutics, A. Goodman-Gilman, T. W. Rail, A. S. Nies, P. Taylor. Pergamon, New York 1990; 485–521
   Google Scholar
• Jastak T. J. Nitrous oxide in dental practice. International Anesthesiology Clinics 1989; 27: 92–97
   PubMed Web of Science ®Google Scholar
• Koob G. E., Markou A., Schulteis G. The mesocorticolimbic system in opioid dependence. Neuropsychopharmacology 1994; 10: 562S, (supplement 1)
   Google Scholar
• Langa H. Relative analgesia in dental practice. W.B. Saunders, Philadelphia 1976
   Google Scholar
• Layzer R. B. Nitrous oxide abuse. Nitrous oxide/N₂O, E. I. Eger, II. Elsevier, New York 1985; 249–257
   Google Scholar
• Lecore A. Effective use of psychotropic analgesic nitrous oxide in modern psychotherapy. International Journal of Neuroscience 1994; 76: 41–48
   PubMedGoogle Scholar
• Lichtigfeld F. J., Gillman M. A. The treatment of alcoholic withdrawal states with oxygen and nitrous oxide. South African Medical Journal 1982; 61: 349–351
   PubMed Web of Science ®Google Scholar
• Lichtigfeld F. J., Gillman M. A. The therapeutic use of opioid substances in psychiatry, with special reference to analgesic concentrations of nitrous oxide. Update of psychiatric management, J. B. Carlile. The Society of Psychiatrists of S.A, Durban 1984; 76–79
   Google Scholar
• Lichtigfeld F. J., Gillman M. A. The effect of placebo in the alcohol withdrawal state. Alcohol and Alcoholism 1989a; 24: 109–112
   PubMed Web of Science ®Google Scholar
• Lichtigfeld F. J., Gillman M. A. Analgesic nitrous oxide for alcohol withdrawal is better than placebo. International Journal of Neuroscience 1989b; 49: 71–74
   PubMed Web of Science ®Google Scholar
• Lichtigfeld F. J., Gillman M. A. Psychotropic analgesic nitrous oxide and neurotransmitter mechanisms involved in the alcohol withdrawal state. International Journal of Neuroscience 1994; 76: 17–33
   PubMedGoogle Scholar
• Lichtigfeld F. J., Gillman M. A. Role of dopamine mesolimbic system in opioid action of psychotropic analgesic nitrous oxide (PAN) in alcohol and drug withdrawal. Clinical Neuropharmacology 1996; 19: 246–251
   PubMed Web of Science ®Google Scholar
• Marx G. F., Bassell G. M. Nitrous oxide in obstetrics. Nitrous oxide/N₂O, E. I. Eger, II. Elsevier, New York 1985; 185–202
   Google Scholar
• Melzack R., Wall P. D. The challenge of pain. Penguin, London 1991; 210–278
   Google Scholar
• Ojutkangas R. Analgesic nitrous oxide: rapid, safe therapy for addictive withdrawal. Postgraduate Medical Journal 1991; 67: 1027–1028
   PubMed Web of Science ®Google Scholar
• Ojutkangas R., Gillman M. A. Psychotropic analgesic nitrous oxide for treating alcohol withdrawal in an outpatient setting. International Journal of Neuroscience 1994; 76: 35–39
   PubMedGoogle Scholar
• Quock R. M., Emmanouil D. E., Vaughn L. K., Pruhs R. J. Benzodiazepine receptor mediation of behavioural effects of nitrous oxide in mice. Psychopharmacology 1992; 107: 310–314
   PubMed Web of Science ®Google Scholar
• Ross H. E. Benzodiazepine use and anxiolytic abuse and dependence in treated alcoholics. Addiction 1993; 88: 209–218
   PubMed Web of Science ®Google Scholar
• Rowland A. S., Baird D. D., Weinberg C. R., Shore D. L., Shy C. M., Wilcox A. J. Reduced fertility among women employed as dental assistants exposed to high levels of nitrous oxide. New England Journal of Medicine 1992; 327: 993–997
   PubMed Web of Science ®Google Scholar
• Sawynok J., Pinsky C., LaBella F. S. Minireview: on the specificity of naloxone as an opiate antagonist. Life Science 1979; 25: 1621–1632
   PubMed Web of Science ®Google Scholar
• Smith R. A., Beirne O. R. The use of nitrous oxide by dentists. Nitrous oxide/N₂O, E. I. Eger, II. Elsevier, New York 1985; 282–304
   Google Scholar
• Spanagel R., Herz A., Shippenberg T. S. Opposing tonically active endogenous opioid systems modulate mesolimbic dopaminergic pathway. Proceedings of the National Acadademy of Science USA 1992; 89: 2046–2050
   PubMed Web of Science ®Google Scholar
• Van Heerden B. B., Price J. C., Jeffrey P. J., Feldman M., Cromwell T., Dannals R. F., Wilson A. A., Ravert H. T., Frost J. J. The effect of nitrous oxide on the endogenous opiate system. South African Medical Journal 1993; 83: 55
   Google Scholar
• Wu K. M., Martin W. R., Kammerling S. G., Wettstein J. G. Possible medullary kappa hyperalgesic mechanism I. A new potential role for endogenous opioid peptides in pain perception. Life Science 1983; 33: 1831–1838
   PubMed Web of Science ®Google Scholar
• Zacny J. P., Lichtor J. L., Coalson D. W., Apfelbaum J. L., Flemming D., Foster V. Time course of effects of brief inhalations of nitrous oxide in normal volunteers. Addiction 1994; 89: 831–839
   PubMed Web of Science ®Google Scholar